101 related articles for article (PubMed ID: 24897389)
1. Downregulation of CIC does not associate with overexpression of ETV1 or MAP kinase pathway activation in gastrointestinal stromal tumors.
Schoppmann SF; Ricken G; Ilhan-Mutlu A; Nirtl N; Streubel B; Preusser M; Birner P
Cancer Invest; 2014 Aug; 32(7):363-7. PubMed ID: 24897389
[TBL] [Abstract][Full Text] [Related]
2. MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1.
Birner P; Beer A; Vinatzer U; Stary S; Höftberger R; Nirtl N; Wrba F; Streubel B; Schoppmann SF
Clin Cancer Res; 2012 Apr; 18(7):1879-87. PubMed ID: 22351694
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of ETV1 and its contribution to tumorigenic phenotypes in gastrointestinal stromal tumors.
Zhang Y; Gu ML; Zhou XX; Ma H; Yao HP; Ji F
Oncol Rep; 2014 Sep; 32(3):927-34. PubMed ID: 24970355
[TBL] [Abstract][Full Text] [Related]
4. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors.
Hapkova I; Skarda J; Rouleau C; Thys A; Notarnicola C; Janikova M; Bernex F; Rypka M; Vanderwinden JM; Faure S; Vesely J; de Santa Barbara P
Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309
[TBL] [Abstract][Full Text] [Related]
5. ETV1 mRNA is specifically expressed in gastrointestinal stromal tumors.
Jang BG; Lee HE; Kim WH
Virchows Arch; 2015 Oct; 467(4):393-403. PubMed ID: 26243012
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of phosphatidylethanolamine binding protein 1 associates with clinical risk factors in gastrointestinal stromal tumors, but not with activation of the RAF-1-MEK-ETV1 pathway.
Schoppmann SF; Beer A; Nirtl N; Ba-Ssalamah A; Brodowicz T; Streubel B; Birner P
Cancer Lett; 2013 Jul; 335(1):26-30. PubMed ID: 23376254
[TBL] [Abstract][Full Text] [Related]
7. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.
Janeway KA; Liegl B; Harlow A; Le C; Perez-Atayde A; Kozakewich H; Corless CL; Heinrich MC; Fletcher JA
Cancer Res; 2007 Oct; 67(19):9084-8. PubMed ID: 17909012
[TBL] [Abstract][Full Text] [Related]
8. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic significance of DOG-1 and PKC-θ expression and c-Kit/PDGFRA mutations in gastrointestinal stromal tumours.
Wang C; Jin MS; Zou YB; Gao JN; Li XB; Peng F; Wang HY; Wu ZD; Wang YP; Duan XM
Scand J Gastroenterol; 2013 Sep; 48(9):1055-65. PubMed ID: 23862765
[TBL] [Abstract][Full Text] [Related]
10. An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST).
Nannini M; Biasco G; Astolfi A; Pantaleo MA
J Med Genet; 2013 Oct; 50(10):653-61. PubMed ID: 23833252
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
Ran L; Sirota I; Cao Z; Murphy D; Chen Y; Shukla S; Xie Y; Kaufmann MC; Gao D; Zhu S; Rossi F; Wongvipat J; Taguchi T; Tap WD; Mellinghoff IK; Besmer P; Antonescu CR; Chen Y; Chi P
Cancer Discov; 2015 Mar; 5(3):304-15. PubMed ID: 25572173
[TBL] [Abstract][Full Text] [Related]
12. Low ETV1 mRNA expression is associated with recurrence in gastrointestinal stromal tumors.
Sakamaki K; Funasaka K; Miyahara R; Furukawa K; Yamamura T; Ohno E; Nakamura M; Kawashima H; Hirooka Y; Fujishiro M; Goto H
Sci Rep; 2020 Sep; 10(1):14767. PubMed ID: 32901065
[TBL] [Abstract][Full Text] [Related]
13. [Expression and gene mutation of phospho-platelet derived growth factor receptor alpha and C-kit in gastrointestinal and extra-gastrointestinal stromal tumors].
Tang M; Li DQ
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jan; 11(1):80-3. PubMed ID: 18197502
[TBL] [Abstract][Full Text] [Related]
14. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
[TBL] [Abstract][Full Text] [Related]
15. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Chi P; Chen Y; Zhang L; Guo X; Wongvipat J; Shamu T; Fletcher JA; Dewell S; Maki RG; Zheng D; Antonescu CR; Allis CD; Sawyers CL
Nature; 2010 Oct; 467(7317):849-53. PubMed ID: 20927104
[TBL] [Abstract][Full Text] [Related]
16. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
Sápi Z; Füle T; Hajdu M; Matolcsy A; Moskovszky L; Márk A; Sebestyén A; Bodoky G
Diagn Mol Pathol; 2011 Mar; 20(1):22-33. PubMed ID: 21326036
[TBL] [Abstract][Full Text] [Related]
17. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
18. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.
Kim WK; Park M; Kim YK; Tae YK; Yang HK; Lee JM; Kim H
Clin Cancer Res; 2011 Dec; 17(24):7584-94. PubMed ID: 22042971
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
Haller F; Gunawan B; von Heydebreck A; Schwager S; Schulten HJ; Wolf-Salgó J; Langer C; Ramadori G; Sültmann H; Füzesi L
Clin Cancer Res; 2005 Sep; 11(18):6589-97. PubMed ID: 16166437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
